文献类型：期刊文献

英文题名：Puerarin prevents LPS-induced osteoclast formation and bone loss via inhibition of Akt activation

作者：Zhang Y.; Yan M.; Yu Q.-F.; Yang P.-F.; Zhang H.-D.; Sun Y.-H.; Zhang Z.-F.; Gao Y.-F.

机构：[1]College of Medicine, Shaoxing University, Huancheng West Road 508, Shaoxing, 312000, China;[2]Department of Biomedical Engineering, College of Life Information Science and Instrument Engineering, Hangzhou Dianzi University, 2nd Avenue 1158, Xiasha Higher Education Zone, Hangzhou, 310018, China;[3]Zhejiang Provincial Key Laboratory of Cardio-Cerebral Vascular Detection Technology and Medicinal Effectiveness Appraisal, Department of Biomedical Engineering, Zhejiang University, Hangzhou, 310027, China

年份：2016

卷号：39

期号：12

起止页码：2028

外文期刊名：Biological and Pharmaceutical Bulletin

收录：Scopus(收录号：2-s2.0-85006109879)

语种：英文

外文关键词：Akt; Bone loss; Lipopolysaccharide (LPS); Osteoclastogenesis; Puerarin

外文摘要：Osteolysis induced by chronic Gram-negative bacterial infection underlies many bone diseases such as osteomyelitis, septic arthritis, and periodontitis. Drugs that inhibit lipopolysaccharide (LPS)-induced osteolysis are critically needed for the prevention of bone destruction in infective bone diseases. In this study, we assessed the effect of puerarin, a natural isoflavone isolated from Pueraria lobata OHWI root, on LPS-induced osteoclastogenesis and bone loss. Our in vitro study showed that puerarin significantly inhibited LPS-induced osteoclast differentiation from osteoclast precursor RAW264.7 cells. The inhibition occurred through suppressing the production of osteoclast activating factor tumor necrosis factor (TNF)-α, interleukin (IL)-1β and prostaglandin E2 (PGE2), which led to down-regulating mRNA expression of osteoclastogenic genes including tartrate-resistant acid phosphatase (TRAP), cathepsin K and matrix metalloprotein 9 (MMP-9). Furthermore, LPS triggered activation of Akt in osteoclast precursor RAW264.7 cells, which was inhibited by puerarin treatment. In vivo, puerarin attenuated LPS-induced bone loss in a murine calvarial osteolysis model. Collectively, puerarin prevents LPS-induced osteoclast formation, function and bone loss, where the inhibition of Akt activation plays an important role. These findings provide evidences that puerarin might be beneficial as a promising candidate drug for the prevention and treatment of bacteria-induced bone destruction disease, and give new insights for understanding its possible mechanism. ? 2016 The Pharmaceutical Society of Japan.